Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEVOPHED vs EPANED
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Norepinephrine acts predominantly on alpha-1 adrenergic receptors to cause vasoconstriction and increase blood pressure. It also has beta-1 adrenergic receptor agonist activity, resulting in positive inotropic effects on the heart.
Epaned contains enalapril maleate, an angiotensin-converting enzyme (ACE) inhibitor. Enalapril is a prodrug that is hydrolyzed to enalaprilat, which inhibits ACE, thereby reducing angiotensin II formation, decreasing vasoconstriction, aldosterone secretion, and sodium reabsorption.
Treatment of hypotension in acute hypotensive states (e.g., septic shock, myocardial infarction, blood loss),Adjunct in the treatment of cardiac arrest (off-label)
Treatment of hypertension,Heart failure (adjunctive therapy with diuretics and digitalis),Asymptomatic left ventricular dysfunction (to reduce the risk of developing overt heart failure)
Initial dose: 8-12 mcg/min intravenously, titrate to desired blood pressure; typical maintenance: 2-4 mcg/min IV continuous infusion.
0.2 mg/kg intravenously over 5 minutes every 2 hours; typical adult dose 10-20 mg IV.
The terminal elimination half-life is approximately 2 minutes. The clinical effect is short-lived due to rapid reuptake and metabolism; continuous intravenous infusion is required for sustained effect.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 10-12 hours in moderate renal impairment (Cr Cl 30-50 m L/min) and 15-20 hours in severe impairment (Cr Cl <30 m L/min).
Primarily metabolized in the liver by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO).
Enalapril is extensively metabolized in the liver by ester hydrolysis to its active form, enalaprilat. No significant CYP450 metabolism.
Norepinephrine is primarily metabolized in the liver and other tissues by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Less than 5% is excreted unchanged in urine. Metabolites are excreted renally (approximately 80-95% as normetanephrine, vanillylmandelic acid, and other conjugates).
Renal excretion of unchanged drug accounts for approximately 30-40% of elimination; biliary/fecal excretion accounts for 50-60% as metabolites and unchanged drug.
Approximately 25-30% bound to albumin and other plasma proteins.
Approximately 85-90% bound to serum albumin.
Approximately 0.7-1.0 L/kg. This indicates moderate distribution into tissues and plasma, consistent with a hydrophilic catecholamine.
0.5-0.7 L/kg, indicating distribution primarily into extracellular fluid.
Bioavailability is 100% via intravenous administration. Oral bioavailability is negligible due to extensive first-pass metabolism; not administered orally. Intramuscular or subcutaneous administration results in erratic absorption and significant vasoconstriction leading to poor bioavailability; thus, intravenous infusion is the only reliable route.
Oral: 70-80% due to first-pass metabolism; Intravenous: 100%.
No specific dose adjustment required for renal impairment; titrate to clinical response.
No adjustment required for renal impairment; drug is hepatically cleared.
No specific dose adjustment required for hepatic impairment; titrate to clinical response.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: use with caution, consider dose reduction by 75%.
Initial: 0.05-0.1 mcg/kg/min IV continuous infusion, titrate to effect; maximum dose not established.
0.2 mg/kg intravenously over 5 minutes every 2 hours; maximum single dose 20 mg.
Start at lower end of dosing range (2-4 mcg/min IV) due to increased sensitivity and comorbidities; titrate cautiously.
Start at lower end of dosing range (0.1 mg/kg) due to potential for decreased hepatic function and increased sensitivity; monitor for QT prolongation.
No FDA boxed warning exists for LEVOPHED.
FDA Warning: When pregnancy is detected, discontinue Epaned as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
Risk of extravasation leading to tissue necrosis; ensure proper IV access and avoid infiltration,Monitor blood pressure, heart rate, and cardiac output continuously,May cause ischemia to limbs, kidneys, and splanchnic organs due to vasoconstriction,Use with caution in patients with hypertension, hyperthyroidism, or myocardial ischemia,Abrupt discontinuation may cause rebound hypotension
Angioedema (including laryngeal edema) risk; discontinue immediately and treat appropriately.,Hypotension in volume-depleted patients (e.g., those on diuretics or with heart failure).,Monitor renal function; risk of acute renal failure, especially in bilateral renal artery stenosis.,Hyperkalemia risk, especially in renal impairment, diabetes, or concomitant K+-sparing diuretics/supplements.,Cough (nonproductive, persistent) may occur.,Hepatic failure; rare but reported. Discontinue if jaundice or significant liver enzyme elevation occurs.
Hypersensitivity to norepinephrine or any component of the formulation,Hypovolemia (should be corrected before or during therapy),Use with cyclopropane or halothane anesthesia (increases risk of ventricular arrhythmias),Severe peripheral vascular disease with risk of gangrene
Hypersensitivity to enalapril or any ACE inhibitor,History of angioedema related to previous ACE inhibitor therapy,Hereditary or idiopathic angioedema,Pregnancy (especially second and third trimesters),Concomitant use with aliskiren in patients with diabetes
No clinically significant food interactions. Monitor for hyperglycemia in diabetic patients due to alpha-adrenergic effects.
No specific food interactions. Grapefruit juice does not affect palonosetron metabolism. Avoid alcohol consumption on chemotherapy days as it may worsen nausea or sedation.
Norepinephrine is a catecholamine that does not cross the placenta extensively. Animal studies have not shown teratogenicity, but human data are limited. Inadequate uteroplacental blood flow due to maternal vasoconstriction may cause fetal hypoxia and bradycardia. Use only if clearly needed, and monitor fetal heart rate. FDA Pregnancy Category C.
Pregnancy category C. No adequate studies in pregnant women. In animal studies, no evidence of teratogenicity at clinically relevant doses. Risk of fetal harm cannot be ruled out. Use only if potential benefit justifies risk.
Norepinephrine is not expected to be excreted into breast milk in clinically significant amounts due to its short half-life and rapid metabolism. M/P ratio not established. Use with caution in breastfeeding women, as effects on the infant are unknown.
Not known if excreted in human milk. Caution advised. M/P ratio unknown.
Pregnancy may alter the pharmacokinetics of norepinephrine, but specific dose adjustments are not established. Monitor maternal blood pressure closely and titrate to the lowest effective dose to maintain adequate uteroplacental perfusion. Starting dose is typically 0.5-1 mcg/min, titrated to effect.
No established dose adjustments for pregnancy. Pharmacokinetic changes in pregnancy are not well characterized; use lowest effective dose.
LEVOPHED (norepinephrine) is a first-line vasopressor for septic shock. Administer via central line to avoid extravasation injury; if extravasation occurs, treat with phentolamine 5-10 mg in 10 m L saline infiltrated locally. Titrate to mean arterial pressure (MAP) ≥ 65 mm Hg. Taper gradually to avoid rebound hypotension.
EPANED (palonosetron) is a 5-HT3 receptor antagonist used for prevention of chemotherapy-induced nausea and vomiting (CINV). It has a longer half-life (~40 hours) than other agents in its class, allowing for single-dose protection. It is not effective for breakthrough nausea. Use caution in patients with electrolyte abnormalities or those taking other QT-prolonging drugs, as palonosetron does not significantly prolong QT interval at standard doses. Administer 30 minutes before chemotherapy. For dexamethasone-sparing regimens, consider single-dose palonosetron with dexamethasone.
This medication is used to treat dangerously low blood pressure.,It will be given intravenously (IV) in a hospital setting by healthcare professionals.,You may feel anxiety, headache, or heart palpitations as the medication works.,Report any pain, redness, or swelling at the IV site immediately.,Do not stop the medication abruptly; it must be tapered under medical supervision.
Take this medication exactly 30 minutes before your chemotherapy session.,This drug prevents nausea and vomiting; it will not help if you already feel sick.,Common side effects include headache, constipation, or diarrhea; report persistent or severe symptoms.,Avoid driving or operating heavy machinery if you feel drowsy or dizzy after taking this medication.,Do not take any other anti-nausea medications without your doctor's approval.,Keep a diary of any vomiting episodes to share with your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEVOPHED vs EPANED, answered by our medical review team.
LEVOPHED is a Vasopressor that works by Norepinephrine acts predominantly on alpha-1 adrenergic receptors to cause vasoconstriction and increase blood pressure. It also has beta-1 adrenergic receptor agonist activity, resulting in positive inotropic effects on the heart.. EPANED is a Vasopressor that works by Epaned contains enalapril maleate, an angiotensin-converting enzyme (ACE) inhibitor. Enalapril is a prodrug that is hydrolyzed to enalaprilat, which inhibits ACE, thereby reducing angiotensin II formation, decreasing vasoconstriction, aldosterone secretion, and sodium reabsorption.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEVOPHED and EPANED depend on the specific clinical indication. These are both Vasopressor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEVOPHED is: Initial dose: 8-12 mcg/min intravenously, titrate to desired blood pressure; typical maintenance: 2-4 mcg/min IV continuous infusion.. The standard adult dose of EPANED is: 0.2 mg/kg intravenously over 5 minutes every 2 hours; typical adult dose 10-20 mg IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEVOPHED and EPANED in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEVOPHED is classified as Category C. Norepinephrine is a catecholamine that does not cross the placenta extensively. Animal studies have not shown teratogenicity, but human data are limited. Inadequate uteroplacental . EPANED is classified as Category C. Pregnancy category C. No adequate studies in pregnant women. In animal studies, no evidence of teratogenicity at clinically relevant doses. Risk of fetal harm cannot be ruled out. . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.